Characterization of cells susceptible to SARS-COV-2 and methods for detection of neutralizing antibody by focus forming assay
E. T. Stone, E. Geerling, T. L. Steffen, M. Hassert, A. Dickson, J. F. Spencer, K. Toth, R. J. DiPaolo, J. D. Brien, A. K. Pinto
Abstract
The SARS-CoV-2 outbreak and subsequent COVID-19 pandemic have highlighted the urgent need to determine what cells are susceptible to infection and for assays to detect and quantify SARS-CoV-2. Furthermore, the ongoing efforts for vaccine development have necessitated the development of rapid, high-throughput methods of quantifying infectious SARS-CoV-2, as well as the ability to screen human polyclonal sera samples for neutralizing antibodies against SARS-CoV-2. To this end, our lab has adapted focus forming assays for SARS-CoV-2 using Vero CCL-81 cells, referred to in this text as Vero WHO. Using the focus forming assay as the basis for screening cell susceptibility and to develop a focus reduction neutralization test. We have shown that this assay is a sensitive tool for determining SARS-CoV-2 neutralizing antibody titer in human, non-human primate, and mouse polyclonal sera following SARS-CoV-2 exposure. Additionally, we describe the viral growth kinetics of SARS-CoV-2 in a variety of different immortalized cell lines and demonstrate via human ACE2 and viral spike protein expression that these cell lines can support viral entry and replication.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies
N. Kruglova, A. E. Siniavin, … D. Mazurov·bioRxiv·May 4, 2021
- A novel in-cell ELISA assay allows rapid and automated quantification of SARS-CoV-2 to analyse neutralizing antibodies and antiviral compounds
L. Schoeler, V. T. K. Le-Trilling, … M. Trilling·bioRxiv·Jun 5, 2020
- Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells
H. Xiong, Y. Wu, … N. Xia·Emerging Microbes & InfectionsPeer-reviewed·Sep 24, 2020
- Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID 19) Virus-Neutralizing Antibodies in Human Clinical Samples
M. R. Holbrook, R. S. Bennett, … V. V. Lukin·bioRxiv·Mar 5, 2021
- Development and validation of IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2
R. Vandergaast, T. Carey, … S. J. Russell·bioRxiv·May 26, 2020
- Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.
J. B. Case, P. W. Rothlauf, … S. P. J. Whelan·bioRxiv·May 18, 2020